Vicky Makker

8.6k total citations · 6 hit papers
180 papers, 4.6k citations indexed

About

Vicky Makker is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Oncology. According to data from OpenAlex, Vicky Makker has authored 180 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Obstetrics and Gynecology, 84 papers in Reproductive Medicine and 66 papers in Oncology. Recurrent topics in Vicky Makker's work include Endometrial and Cervical Cancer Treatments (100 papers), Ovarian cancer diagnosis and treatment (75 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Vicky Makker is often cited by papers focused on Endometrial and Cervical Cancer Treatments (100 papers), Ovarian cancer diagnosis and treatment (75 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Vicky Makker collaborates with scholars based in United States, Spain and Italy. Vicky Makker's co-authors include Ana Oaknin, Carol Aghajanian, Matthew H. Taylor, Corina E. Dutcus, Daniel E. Stepan, Robert Shumaker, Nadeem R. Abu‐Rustum, Kaled M. Alektiar, Drew Rasco and Douglas A. Levine and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Vicky Makker

166 papers receiving 4.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

2023 432 citations Funda Meric‐Bernstam, Vicky Makker et al. Journal of Clinical Oncology profile →
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

2019 360 citations Vicky Makker, Marcia S. Brose et al. profile →
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

2020 359 citations Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology profile →
Endometrial cancer

2021 340 citations Vicky Makker, Helen Mackay et al. profile →
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

2020 306 citations Matthew H. Taylor, Vicky Makker et al. Journal of Clinical Oncology profile →
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 304 citations Ana Oaknin, Domenica Lorusso et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Vicky Makker

Since Specialization

Citations

This map shows the geographic impact of Vicky Makker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vicky Makker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vicky Makker more than expected).

Fields of papers citing papers by Vicky Makker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vicky Makker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vicky Makker. The network helps show where Vicky Makker may publish in the future.

Co-authorship network of co-authors of Vicky Makker

This figure shows the co-authorship network connecting the top 25 collaborators of Vicky Makker. A scholar is included among the top collaborators of Vicky Makker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vicky Makker. Vicky Makker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate 2025 ·Gynecologic Oncology ·Paul Johannet, (unknown), M. Herman Chui, Jason Konner, Claire F. Friedman, Angela K. Green, Robin Guo, Martee L. Hensley, Chrisann Kyi, Ying Liu, Vicky Makker, Maria M. Rubinstein, Paul Sabbatini, William P. Tew, Michael B. Foote, Britta Weigelt, Carol Aghajanian, Rachel N. Grisham, (unknown)	0
2	Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma 2025 ·International Journal of Gynecological Cancer ·(unknown), (unknown), (unknown), Ben Davidson, Lora H. Ellenson, Qin Zhou, Alexia Iasonos, Jennifer J. Mueller, Kaled M. Alektiar, Vicky Makker, Jacqueline Feinberg, (unknown), (unknown), (unknown), Mario M. Leitão, Nadeem R. Abu-Rustum, Ane Gerda Zahl Eriksson	1
3	145P Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1 2025 ·Annals of Oncology ·J-Y. Lee, Funda Meric‐Bernstam, Ana Oaknin, D-Y. Oh, Soham D. Puvvada, Robert McEwen, Flavia Michelini, Vicky Makker	1
4	A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer 2024 ·Gynecologic Oncology ·Eugenia Girda, Vicky Makker, Christian Marth, Toon Van Gorp, Mansoor Raza Mirza, (unknown), (unknown), Roman Groisberg, Fan Jin, David M. O’Malley	1
5	Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer 2024 ·Journal of Gynecologic Oncology ·Kan Yonemori, Keiichi Fujiwara, Kosei Hasegawa, Mayu Yunokawa, Kimio Ushijima, Shiro Suzuki, Ayumi Shikama, Shinichiro Minobe, Tomoka Usami, Jae‐Weon Kim, Byoung‐Gie Kim, Peng‐Hui Wang, Ting‐Chang Chang, Keiko Yamamoto, (unknown), Jodi A. McKenzie, Robert Orlowski, Takuma Miura, Vicky Makker, Yong Man Kim	8
6	A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer. 2024 ·Journal of Clinical Oncology ·Angela Green, Qin Zhou, Alexia Iasonos, (unknown), Britta Weigelt, Lora H. Ellenson, (unknown), (unknown), (unknown), Joseph P. Erinjeri, Iva Petkovska, Sarat Chandarlapaty, (unknown), Rachel N. Grisham, Jason Konner, Maria M. Rubinstein, William P. Tew, Tiffany A. Troso-Sandoval, Carol Aghajanian, Vicky Makker	4
7	Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 2024 ·Advances in Therapy ·Ana Oaknin, Jung‐Yun Lee, Vicky Makker, Do‐Youn Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, (unknown), Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Soham D. Puvvada, (unknown), Funda Meric‐Bernstam	9
8	748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775 2023 ·Annals of Oncology ·Émeline Colomba, Domenica Lorusso, Helen Mackay, Richard G. Moore, Kan Yonemori, (unknown), (unknown), (unknown), Gianmaria Barresi, Jodi A. McKenzie, Vicky Makker	2
9	HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer 2023 ·Modern Pathology ·Sherry Shen, Weining Ma, David N. Brown, Arnaud Da Cruz Paula, Qin Zhou, (unknown), Basile Tessier‐Cloutier, Dara S. Ross, Tiffany A. Troso-Sandoval, Jorge S. Reis‐Filho, Nadeem R. Abu‐Rustum, Yanming Zhang, Lora H. Ellenson, Britta Weigelt, Vicky Makker, M. Herman Chui	12
10	LBA34 Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study 2023 ·Annals of Oncology ·Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, D-Y. Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Yanhui Ma, Soham D. Puvvada, J-Y. Lee	3
11	A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update 2023 ·Journal of Clinical Oncology ·Vicky Makker, Carol Aghajanian, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Mark Messing, Lea Dutta, Corina E. Dutcus, Jie Huang, Emmett V. Schmidt, Robert Orlowski, Matthew H. Taylor	25
12	Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab 2023 ·The Oncologist ·Nicoletta Colombo, Domenica Lorusso, Bradley J. Monk, Brian M. Slomovitz, Kosei Hasegawa, Angélica Nogueira‐Rodrigues, (unknown), Chinyere E. Okpara, (unknown), Jodi A. McKenzie, Vicky Makker	4
13	2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies 2022 ·International Journal of Gynecological Cancer ·Nicole Concin, Manish R. Patel, Vicky Makker, Ana Oaknin, Sandro Pignata, Floor Backes, Antonio González-Martı́n, Ramez N. Eskander, Bhavana Pothuri, Debra L. Richardson, Angeles Alvarez Secord, Els Van Nieuwenhuysen, Joyce F. Liu, Fernanda Musa, Richard T. Penson, Kenton Wride, Rachel L. Dusek, T. Cameron, Erika Hamilton	0
14	2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775 2022 ·International Journal of Gynecological Cancer ·Domenica Lorusso, Vicky Makker, Antonio Casado, Bradley J. Monk, Helen Mackay, Alessandro D. Santin, David S. Miller, Richard G. Moore, Sally Baron‐Hay, Isabelle Ray‐Coquard, Ronnie Shapira‐Frommer, Kimio Ushijima, Kan Yonemori, Yong Man Kim, Eva María Guerra Alia, Ulus Ali Şanlı, (unknown), Jodi A. McKenzie, (unknown), Nicoletta Colombo	1
15	GermlineSMARCA4Deletion as a Driver of Uterine Cancer: An Atypical Presentation 2022 ·JCO Precision Oncology ·(unknown), Duaa H. Al-Rawi, Vicky Makker, Britta Weigelt, Dmitriy Zamarin, Ying L. Liu, Angela G. Arnold, M. Herman Chui, Diana Mandelker, Michael F. Walsh, Deborah F. DeLair, Karen A. Cadoo, Roisin E. O’Cearbhaill	3
16	Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition 2022 ·American Journal of Ophthalmology Case Reports ·William Foulsham, (unknown), (unknown), Vicky Makker, Jason Konner, David H. Abramson, Jasmine H. Francis	4
17	Safety and Efficacy of Arterially Directed Liver Therapies in the Treatment of Hepatic Metastatic Ovarian Cancer: A Retrospective Single-Institution Study 2021 ·Journal of Vascular and Interventional Radiology ·(unknown), (unknown), (unknown), Lynn A. Brody, Joseph P. Erinjeri, Etay Ziv, F. Edward Boas, Constantinos T. Sofocleous, Mikhail Silk, Vicky Makker, William P. Tew, Hooman Yarmohammadi	3
18	Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer breakdown → 2020 ·Journal of Clinical Oncology ·Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Daniel E. Stepan, Corina E. Dutcus, Jane Wu, Emmett V. Schmidt, Robert Orlowski, Perminder S. Sachdev, Robert Shumaker, Antonio Casado	359
19	Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders 2018 ·Clinical Cancer Research ·Rachel N. Grisham, Kathleen N. Moore, Michael S. Gordon, Wael A. Harb, (unknown), Darragh Halpenny, Vicky Makker, Carol Aghajanian	22
20	Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors 2018 ·Clinical Cancer Research ·David M. Hyman, Naiyer A. Rizvi, Ronald B. Natale, Deborah K. Armstrong, Michael J. Birrer, Lawrence D. Recht, Efrat Dotan, Vicky Makker, Thomas Kaley, (unknown), Matthew Gribbin, Jennifer McDevitt, Dominic W. Lai, Mohammed M. Dar	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact